loading page

Bibliometric analysis of global research on human organoids
  • +1
  • Huanyu Li,
  • Daofeng Wang,
  • Ho Cheong Wong,
  • Dan Shan
Huanyu Li
China Medical University
Author Profile
Daofeng Wang
Capital Medical University
Author Profile
Ho Cheong Wong
Clinical Science Institute, University Hospital Galway
Author Profile
Dan Shan
Regenerative Medicine Institute

Corresponding Author:[email protected]

Author Profile


Background: Animal models play a crucial role in medicine and biology, but they can’t fully replace human models for studying human biology, disease mechanisms, and drug efficacy. Human organoids offer an opportunity to investigate human diseases and complement animal models. However, research on human organoids lacks comprehensive characterizations. Objective: Identify and describe publications exploring and applying organoids. Methods: Thorough analysis of articles from the past two decades retrieved from Web of Science core collection database. Examined publication year, authors, institutions, countries, references, and keywords. Reviewed top 100 highly cited articles using CiteSpace. Results: Found 6817 original articles on organoids, with a remarkable surge over the past decade (nearly 70-fold increase since 2009). Collaboration among the United States, China, Germany, Netherlands, England, and Japan was prominent. Key figures advancing this field include Clevers Hans, Van Der Laan, Jason R. Spence, and Sato Toshiro. Top articles covered basic research (39%), stem cell development, interactions; biobanking (9%) for organoid cultivation; precision medicine (15%) in cell therapy, drug development; disease modeling (37%) involving pathogen analysis, genetic variant screening. Challenges: high costs, technological barriers, lack of standardized protocols, precise immune system establishment, limited quality clinical trials. Overcoming these requires collaborative efforts, evaluation guidelines. Conclusions: Organoid research focuses on basic research, disease modeling, precision medicine, and biobanking. Prioritizing cost reduction, technology sharing, international standards, and high-quality clinical trials is crucial.